炎症性肠病的创新、补充和替代疗法:2020年的广泛更新

L. Masi, C. Ciuffini, V. Petito, L. Pisani, L. Lopetuso, C. Graziani, D. Pugliese, L. Laterza, P. Puca, F. Di Vincenzo, M. Pizzoferrato, D. Napolitano, L. Turchini, V. Amatucci, E. Schiavoni, G. Privitera, L. Minordi, M. C. Mentella, A. Papa, A. Armuzzi, A. Gasbarrini, F. Scaldaferri
{"title":"炎症性肠病的创新、补充和替代疗法:2020年的广泛更新","authors":"L. Masi, C. Ciuffini, V. Petito, L. Pisani, L. Lopetuso, C. Graziani, D. Pugliese, L. Laterza, P. Puca, F. Di Vincenzo, M. Pizzoferrato, D. Napolitano, L. Turchini, V. Amatucci, E. Schiavoni, G. Privitera, L. Minordi, M. C. Mentella, A. Papa, A. Armuzzi, A. Gasbarrini, F. Scaldaferri","doi":"10.3389/fgstr.2022.1022530","DOIUrl":null,"url":null,"abstract":"Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update\",\"authors\":\"L. Masi, C. Ciuffini, V. Petito, L. Pisani, L. Lopetuso, C. Graziani, D. Pugliese, L. Laterza, P. Puca, F. Di Vincenzo, M. Pizzoferrato, D. Napolitano, L. Turchini, V. Amatucci, E. Schiavoni, G. Privitera, L. Minordi, M. C. Mentella, A. Papa, A. Armuzzi, A. Gasbarrini, F. Scaldaferri\",\"doi\":\"10.3389/fgstr.2022.1022530\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.\",\"PeriodicalId\":73085,\"journal\":{\"name\":\"Frontiers in gastroenterology (Lausanne, Switzerland)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in gastroenterology (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fgstr.2022.1022530\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in gastroenterology (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgstr.2022.1022530","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

炎症性肠病(IBD)是一种慢性致残疾病,具有复杂的多因素病因,目前仍未完全了解。在过去的20年里,抗tnf -α拮抗剂已经彻底改变了IBD的治疗,但许多患者仍然没有反应或经历不良事件。因此,针对几种不同肠道炎症途径的新的生物疗法和小分子已经被开发出来,其中一些已经被引入临床实践,而许多其他的正在研究中。此外,目前正在研究白细胞清除、粪便微生物群移植和干细胞移植等治疗方法来治疗IBD。最后,补充和替代医学已成为胃肠病学家感兴趣的领域,以减轻IBD患者的症状负担。在这篇全面和最新的综述中,提供了当前和正在开发的药物的新分类。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update
Inflammatory bowel diseases (IBD) are chronic disabling conditions with a complex and multifactorial etiology, which is still not completely understood. In the last 20 years, anti-TNF-α antagonists have revolutionized the treatment of IBD, but many patients still do not respond or experience adverse events. Therefore, new biological therapies and small molecules, targeting several different pathways of gut inflammation, have been developed of which some have already been introduced in clinical practice while many others are currently investigated. Moreover, therapeutic procedures such as leukocytapheresis, fecal microbiota transplant and stem cell transplantation are currently being investigated for treating IBD. Lastly, complementary and alternative medicine has become a field of interest for gastroenterologist to reduce symptom burden in IBD patients. In this comprehensive and updated review, a novel classification of current and developing drugs is provided.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Current status and clinical applications of tissue engineering of the gastrointestinal tract: a systematized narrative review Fecal microbiota transplantation—could stool donors’ and receptors’ diet be the key to future success? X-ray phase-contrast 3D virtual histology characterises complex tissue architecture in colorectal cancer Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason A blood-based transcriptomic signature stratifies severe Crohn’s disease and defines potentially targetable therapeutic pathways
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1